The abstract is read at the publisher; the summary is JClub's.
Transcriptional CDKs are emerging therapeutic candidates because they regulate RNAPII transcription across initiation, elongation, termination, and later stages, enabling targetable vulnerabilities in cancer.
- Why it matters: Cell-cycle CDKs have dominated drug discovery, but dysregulated co-transcriptional processes in cancer may create vulnerabilities that transcriptional CDK targeting could exploit.
- What they did: This Review synthesizes current mechanistic understanding of how CDKs control RNAPII transcription and surveys therapeutic strategies, including reversible and covalent inhibitors, degraders, molecular glues, and bivalent proximity-inducing modalities.
- The result: The work outlines key mechanistic, translational, and clinical challenges that must be addressed to realize therapeutic potential of targeting transcriptional CDKs in cancer and inflammation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.